Dean

Prior Positions

2020-2023 Chairman in Institute of Biopharmaceutical Sciences, NYCU
2019-2022 Board Director at PharmaEngine Inc. (Legal Representative of NDF, EY)
2018-2020 Deputy Director in Biomedical Engineering Research and Development Center, NYCU
2018-2020 Coach of SPARK program at National Yang Ming Chiao Tung University
2011-2019 Professor in Institute of Biopharmaceutical Sciences, National Yang-Ming University
2011-2017 Chairman in Institute of Biopharmaceutical Sciences, National Yang-Ming University
2007-2011 Professor in Institute of Clinical Medicine, National Yang-Ming University
2005-2007 Associate Investigator in Institute of Cancer Research, National Health Research Institutes
2003-2005 Associate Investigator in Division of Molecular and Genomic Medicine, NHRI
1998-2003 Assistant Investigator in Division of Molecular and Genomic Medicine, NHRI
1994-1998 Postdoc in Molecular Pharmacology (Laboratory of James E. Ferrell, Jr., Stanford University)

Research

Selected corresponding author publications: (214 papers)

1. Extracellular Vesicular Delta-Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer Diagnosis. Advanced Science 12(22):e2416711 (2025)
2. Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions. Cancer Cell International 25(1):79 (2025)
3. Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer. Cell Death Discovery 11:26 (2025)
4. Engineered Extracellular Vesicles Carrying Let-7a-5p for Alleviating Inflammation in Acute Lung Injury. Journal of Biomedical Science 31:30 (2024)
5. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis. Advanced Science 11:e2306373 (2024)
6. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Nature Communications 14:6692 (2023)
7. Repurposing thioridazine for inducing immunogenic cell death in colorectal cancer via eIF2α/ATF4/CHOP and secretory autophagy pathways. Cell Communication and Signaling 21:184. (2023)
8. BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death. Cell Communication and Signaling 20(1):200. (2022)
9. Mesenchymal stem cell secreted-extracellular vesicles are involved in chondrocyte production and reduce adipogenesis during stem cell differentiation Tissue Engineering and Regenerative Medicine 19:1295–1310 (2022)
10. Identification of Thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death and Disease 6:e1753 (2015).
11. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. American Journal of Respiratory and Critical Care Medicine, 186(11):1180-1188 (2012)

First and Second Dean (2016 to July 2022)

Professor Kang, Jaw-Jou

Position

Institute of Food Safety and Health Risk Assessment, NYCU Emeritus Professor

Email

jjkang@nycu.edu.tw

Degree

Ph.D. in Chemistry, UCSD

Specialty

◆Cellular and molecular Toxicology
◆ Effects of chemicals and drugs on receptors and enzymes of plasma membranes
◆ Roles of calcium in chemically induced cytotoxicity

Third Dean (August 2022 to July 2025)

Professor Anya Maan-Yuh Lin

Position

Acting Director in Institute of Food Safety and Health Risk Assessment

Professor of Pharmacy Department

Joint appointments: Ph.D. Program in Regulatory Science and Policy, Institute of Biopharmaceutical Sciences, Institute of Pharmacology, Department & Institute of Physiology

Email

myalin@nycu.edu.tw

Degree

PhD, Pharmacology, Colorado State University, USA 

Specialty

CNS Neuropharmacology, Translational research